Drug Profile
MEDI 559
Alternative Names: MEDI-559; RSV vaccine (MEDI-559)Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Developer MedImmune
- Class Respiratory syncytial virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 31 Mar 2015 Discontinued - Phase-I/II for Respiratory syncytial virus infections (In infants, Prevention) in USA (Intranasal)
- 01 Aug 2012 MedImmune completes a phase I/II trial for prevention of Respiratory syncytial virus infections in USA (NCT00767416)
- 06 Jul 2009 MEDI 559 is still in phase I/II trials for prevention of Respiratory syncytial virus infections in healthy infants in USA